<div id="readability-page-1"><p>Ampliphi Biosciences Corp (NYSEAMERICAN:APHB - Get Free Report) was up 9.3% on Wednesday . The stock traded as high as $9.59 and last traded at $9.54. Approximately 133,273 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 842,200 shares. The stock had previously closed at $8.73.</p><div><p><span></span><span>Get <strong>Ampliphi Biosciences</strong> alerts:</span></p></div><h2>Ampliphi Biosciences Stock Performance</h2><p>The business has a 50 day moving average of $6.96 and a 200-day moving average of $5.17. </p><h2>Ampliphi Biosciences Company Profile</h2> (Get Free Report)<p>Ampliphi Biosciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of novel therapies to prevent and treat life‐threatening drug‐resistant infections. The company's core mission is to address the growing global threat of antibiotic resistance by advancing first‐in‐class and best‐in‐class antibacterial agents through late‐stage clinical trials.  </p><p>The company's lead product candidate, exeporfinium chloride (XF-73), is a pioneering topical antibacterial designed for pre‐operative nasal decolonization of Staphylococcus aureus in patients undergoing high‐risk surgical procedures.</p><h2>Read More</h2><ul><li>Five stocks we like better than Ampliphi Biosciences</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>This makes me furious</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Ampliphi Biosciences Right Now?</h2><p>Before you consider Ampliphi Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ampliphi Biosciences wasn't on the list.</p><p>While Ampliphi Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Ampliphi Biosciences (NYSEAMERICAN:APHB) saw a stock price increase of 9.3%, trading at $9.54 after reaching a high of $9.59. Despite this rise, trading volume was down 84% from the average, with 133,273 shares exchanged. The company focuses on developing therapies for drug-resistant infections, with its lead product being exeporfinium chloride for pre-operative nasal decolonization. Analysts currently rate the stock as a Hold, suggesting there may be better investment options available.</p>

Market Beat

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

VG Health

SPDR S&P Biotech

APTOSE BIOSCIENCES INC

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

MBX Biosciences

iShares Biotechnology ETF

iShares US Pharma

Invesco Nasdaq Biotechnology ETF

Ampliphi Biosciences (NYSEAMERICAN:APHB) Trading Up 9.3%  - What's Next?